Ruti Aga: Six-Year Ban Over a Forged Prescription Effectively Ends a Marathon Career

The Athletics Integrity Unit (AIU) has banned Ethiopian marathon runner Ruti Aga for six years. According to the statement issued on Thursday, the sanction is not the product of a single incident but the sum of two separate violations. The first is the presence of the prohibited substance methylprednisolone in a sample taken at a half marathon in China in March, which carries two years. The second is tampering — submitting a forged medical prescription during the investigation — which carries four years. Together, six years, calculated from 10 September, the same date on which she was provisionally suspended. Aga won that half marathon, and the in-competition sample returned an adverse finding. She told investigators the drug had been administered to treat a knee injury. But when the agency verified the prescription, it found that the supposed doctor was a family member with no medical registration; that the clinic named on the document did not exist; and that the clinic, when contacted, explicitly disowned the prescription. The family member claimed to have used an old prescription pad from a former workplace. The document failed at three independent verification points. The arithmetic of the sanction is revealing in itself. Under the Code, a presence violation normally attracts two years, particularly where the substance is a Specified Substance and intent is not established. The standard sanction for tampering is four years. The sum lands exactly on six. The direct implication is that the panel declined the no-significant-fault mitigation that would ordinarily reduce the presence sanction. In other words, the panel treated the substance charge as proven without aggravating intent, but treated the document fraud as fully culpable conduct. A significant technical correction is necessary here, because the entire legal architecture of the case rests on it. Several reports described methylprednisolone as a prohibited steroid and stated that WADA classes it as performance enhancing. That is imprecise and misleading. Methylprednisolone is a glucocorticoid, not an anabolic steroid. On the WADA Prohibited List it falls under class S9, not S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only when administered by injection, orally or rectally. A therapeutic injection given out of competition is entirely lawful. The consequence is that the case never turned on steroid use. It turned on two technical questions: by which route the drug was given, and how long before the race. Intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. Aga therefore had a legitimate defence available: that this was treatment, not doping, supported by correct timing, correct route and genuine medical records. By fabricating the prescription, she destroyed precisely the defence that might have worked. The most troubling element of the case is not the substance but the state of her medical support. An athlete with a credentialed team physician would either have held or applied for a Therapeutic Use Exemption, or observed WADA's route-specific washout period. Neither appears to have happened. Instead, a prescription was produced by an unregistered family member. That is not a clerical error; it is the signature of an athlete operating without a qualified team doctor. The knee injury is the true root cause, and it signals a systemic problem rather than an individual one. Chronic knee pathology is a well-known load-bearing limit in high-volume marathoners. Injured runners face strong pressure to mask pain and keep racing, because appearance fees and contracts depend on it. Glucocorticoids are the cheapest, most readily available tool for suppressing that pain. And where the surrounding medical network is informal, a forged prescription is exactly what fills the gap. In career terms the sanction is functionally a lifetime ban. Aga is 32. Six years from 10 September means a return at roughly 38. Ethiopia's women's marathon depth is so extreme that a 38-year-old with a doping record is effectively unselectable for the national team. The ban removes her from the 2028 Olympic cycle entirely. Notably, the two-year presence sanction was probably survivable; the six-year figure was created by her own conduct — the document fraud. Her competitive record does not appear to be erased wholesale, though official confirmation is awaited. She won the 2026 Tokyo Marathon and finished second at three World Marathon Majors. The violation is anchored to a March race in a later year, and absent evidence of earlier use, results before that date are not automatically annulled. The statement does not specify the scope of disqualification. Under standard AIU practice, however, the result and prize money from the race at which the sample was collected are all but certain to be voided. The competitive landscape is essentially unaffected. Ethiopia's depth is such that the removal of a 2:18 to 2:20 performer does not measurably alter national-team capacity. Her three Major second places were commercial-tier results, not championship conversions. Ethiopia currently holds the world-record end of the event; Kenya converts more reliably in championship races. Both nations are structurally deep, and both are equally exposed to entourage-level governance failure. A structural shift is visible nonetheless. China's Label road-race circuit has long been a lucrative, low-risk income tier for East African marathoners between Majors. It is now also the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. Integrity risk attached to results at this tier will rise, and athlete advisers will have to treat paper medical records as seriously as race preparation. The legal route remains open, but its prospects are poor. The CAS appeal window typically runs about 21 days from the reasoned decision. The central finding here, however, is document-based: a clinic that does not exist, a person with no registration, a pad the clinic itself disowned. Such facts are very hard to overturn. There may have been room to challenge the two-year presence sanction; challenging the four-year tampering sanction is close to futile, and that is what produced the six-year total. The larger question is proportionality. The substance at the centre of a six-year ban has no proven endurance benefit. A glucocorticoid reduces pain and inflammation; it does not build muscle the way an anabolic steroid does. The outcome will therefore be cited both ways — as evidence of AIU rigour, and as evidence of disproportionate enforcement against African road runners. That debate is legitimate, but it should not be conducted on a false premise: the sanction is heavy not because of the substance, but because of the forgery. A pattern is also worth noting. Tampering charges are increasingly common in AIU road-racing cases, which suggests the enforcement frontier has shifted from detection to document verification. Aga's case is not an outlier but part of a recognisable family in which an initial substance violation is compounded by a fabricated explanation. And because the same informal medical networks serve many athletes in the same training clusters, further cases are likely to surface. The conclusion is clear. Ruti Aga's six-year ban was delivered not by a substance but by a piece of paper. With genuine records of the knee treatment and correct timing and route, the case might never have existed, or would have resolved with mitigation. Instead, a runner with a 2026 Tokyo title and three Major second places stands at the end of her career with an integrity record attached to it. Ethiopia's team will not notice. The sport's medical governance should.